What’s the current market cap for Mirum Pharmaceuticals stock?

Mirum Pharmaceuticals (MIRM) has a market cap of $5.6bn as of June 04, 2026.

What is the P/E ratio for Mirum Pharmaceuticals stock?

The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of June 04, 2026.

Does Mirum Pharmaceuticals stock pay dividends?

No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of June 04, 2026.

When is the next Mirum Pharmaceuticals dividend payment date?

Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.

What is the beta indicator for Mirum Pharmaceuticals?

Mirum Pharmaceuticals (MIRM) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Mirum Pharmaceuticals stock | $MIRM Share Price

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Ticker

$MIRM

Sector

Health

Primary listing

NASDAQ

Employees

418

Headquarters

Foster City, United States

Website

www.mirumpharma.com

MIRM Metrics

BasicAdvanced

$5.6bn

-

-$15.17

0.52

-

What the Analysts think about MIRM

Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.

Bulls say / Bears say

Mirum’s acquisition of Bluejay Therapeutics for up to USD 820 million adds brelovitug—a late-stage monoclonal antibody for chronic hepatitis D with 100% virologic response in mid-stage trials—to its rare disease pipeline, bolstering long-term growth prospects (Reuters).

Volixibat met the primary endpoint in the VISTAS Phase 2b study by significantly reducing pruritus in primary sclerosing cholangitis patients, supporting Mirum’s first-in-class positioning and planned NDA submission in H2 2026 (Reuters).

Mirum priced USD 600 million of zero-coupon convertible senior notes due 2032 at a 30% equity premium, securing non-dilutive funding to accelerate R&D and strategic expansion while optimizing its capital structure (Reuters).

Mirum’s Q1 operating expenses surged to USD 949.3 million in Q1 2026, driving a net loss of USD 790.2 million and straining its path to profitability amid hefty acquisition-related charges (Reuters).

Shares of Mirum fell 2% following its announcement of a USD 600 million convertible bond offering, reflecting investor concern over increased debt obligations and potential equity dilution (Reuters).

Topline data from the VANTAGE Phase 2b study of volixibat in primary biliary cholangitis is not expected until Q1 2027, delaying potential market expansion and leaving Mirum reliant on its existing products for a prolonged period (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

MIRM Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

MIRM Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

MIRM News

AllArticlesVideos

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Business Wire·4 hours ago

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Business Wire·5 days ago

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

MarketBeat·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Mirum Pharmaceuticals

Ticker

Employees

MIRM Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about MIRM

Analyst Ratings

Bulls say / Bears say

MIRM Financial Performance

Income Statement

MIRM Earnings Performance

Earnings per share (EPS)

MIRM News

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Buy $MIRM

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Mirum Pharmaceuticals/$MIRM

About Mirum Pharmaceuticals

Ticker

Employees

MIRM Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about MIRM

Analyst Ratings

Bulls say / Bears say

MIRM Financial Performance

Income Statement

MIRM Earnings Performance

Earnings per share (EPS)

MIRM News

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Buy $MIRM

Upcoming events

No upcoming events

What’s the current market cap for Mirum Pharmaceuticals stock?

What is the P/E ratio for Mirum Pharmaceuticals stock?

Does Mirum Pharmaceuticals stock pay dividends?

When is the next Mirum Pharmaceuticals dividend payment date?

What is the beta indicator for Mirum Pharmaceuticals?

Bulls say / Bears say